Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel M Silver

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Oncology Practice|September 22, 2010
Cancer care for the whole patient-a new institute of medicine reportSamuel M Silver
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
NCCN: The Future is BrightSamuel M Silver
Clinical Advances in Hematology & Oncology : H&O|February 19, 2008
Updated clinical practice guidelines on erythropoiesis-stimulating agentsSamuel M Silver
Journal of Oncology Practice|February 16, 2018
The American Society of Hematology: Advancing Knowledge and Treatment of Blood DisordersSamuel M Silver
Journal of Oncology Practice|January 7, 2016
Pharmaceutical Industry Influence on Duplicate Abstracts at National Oncology and Hematology MeetingsSamuel M Silver
Journal of Oncology Practice|September 28, 2010
Academic and Community-Based Cancer Centers: it's an Uncertain World and the Journal of Oncology Practice Will Follow it CloselySamuel M Silver, Michael Goldstein
Cancer Journal (Sudbury, Mass.)|April 9, 2008
Erythropoietin-stimulating agents in oncologyMichael R Savona, Samuel M Silver
JAMA Oncology|February 3, 2022
Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be DeterminedDouglas W Blayney, Samuel M Silver
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
University of Michigan Comprehensive Cancer Center opportunities for improvement projectTara M Breslin, Marcy Waldinger, Samuel M Silver
The Journal of Dermatology|January 6, 2025
Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyriaSamuel M Silver, Katherine Houghton, Abby Hitchens, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Oncology Practice|September 22, 2010
Cancer care for the whole patient-a new institute of medicine reportSamuel M Silver
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
NCCN: The Future is BrightSamuel M Silver
Clinical Advances in Hematology & Oncology : H&O|February 19, 2008
Updated clinical practice guidelines on erythropoiesis-stimulating agentsSamuel M Silver
Journal of Oncology Practice|February 16, 2018
The American Society of Hematology: Advancing Knowledge and Treatment of Blood DisordersSamuel M Silver
Journal of Oncology Practice|January 7, 2016
Pharmaceutical Industry Influence on Duplicate Abstracts at National Oncology and Hematology MeetingsSamuel M Silver
Journal of Oncology Practice|September 28, 2010
Academic and Community-Based Cancer Centers: it's an Uncertain World and the Journal of Oncology Practice Will Follow it CloselySamuel M Silver, Michael Goldstein
Cancer Journal (Sudbury, Mass.)|April 9, 2008
Erythropoietin-stimulating agents in oncologyMichael R Savona, Samuel M Silver
JAMA Oncology|February 3, 2022
Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be DeterminedDouglas W Blayney, Samuel M Silver
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
University of Michigan Comprehensive Cancer Center opportunities for improvement projectTara M Breslin, Marcy Waldinger, Samuel M Silver
The Journal of Dermatology|January 6, 2025
Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyriaSamuel M Silver, Katherine Houghton, Abby Hitchens, et al.
Pageof 3